Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Inflammatory Myopathies
NCT07355257Phase 3Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 3 trial of telitacicept in inflammatory myopathy (IIM). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07355257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355257.